Organon (OGN) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organon (OGN) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 30.1% versus a gain of 11.8%. Telix Pharmaceuticals is the larger company by market cap ($3.74 billion vs $3.62 billion), about 1.0 times the size. On valuation, Organon trades at a lower trailing P/E (17.7x vs 110.2x for Telix Pharmaceuticals).
Organon pays a dividend yielding 0.58%, while Telix Pharmaceuticals does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGN | TLX |
|---|---|---|
| Share price | $13.80 | $11.02 |
| Market cap | $3.62B | $3.74B |
| 1-day change | +0.07% | -0.90% |
| YTD return | +92.33% | +48.46% |
| 1-year return | +30.09% | +11.76% |
| 5-year return | -60.48% | — |
| P/E ratio (TTM) | 17.69 | 110.20 |
| Forward P/E | 3.82 | — |
| EPS (TTM) | $0.78 | $0.10 |
| Dividend yield | 0.58% | 0.00% |
| Annual dividend | $0.08 | $0.00 |
| Revenue (latest FY) | $6.22B | $803.79M |
| Revenue growth (YoY) | -2.92% | +55.61% |
| Net income (latest FY) | $187.00M | $-7.13M |
| Gross margin | 53.30% | 53.05% |
| Operating margin | — | 3.70% |
| Net margin | 3.01% | -0.89% |
| 52-week high | $13.80 | $13.11 |
| 52-week low | $5.69 | $6.28 |
| Distance from 52-week high | 0.00% | -15.94% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -18.48% | +85.30% |
| Average volume | 2.64M | 258.23K |
| Shares outstanding | 262.61M | 339.78M |
| Employees | 10,000 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed TLX by 18.3 percentage points over the past year.
- Telix Pharmaceuticals trades at a higher earnings multiple (110.2x vs 17.7x trailing P/E).
- Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs -2.92%).
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
OGN vs TLX FAQ
Which is bigger, Organon or Telix Pharmaceuticals?
Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $3.74B compared with $3.62B for Organon (OGN).
Which stock has performed better over the past year, OGN or TLX?
OGN returned +30.09% over the past 12 months, compared with +11.76% for TLX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, OGN or TLX?
OGN has the lower trailing P/E at 17.7, versus 110.2 for TLX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Organon or Telix Pharmaceuticals?
Organon pays a dividend yielding 0.58%, while Telix Pharmaceuticals does not currently pay a regular dividend.
Are Organon and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.